Clinical trials: insulin glargine
Diabetes Mellitus, Insulin-Dependent
Insulin Pump Therapy in Adolescents With Newly Diagnosed Type 1 Diabetes (T1D)
Within 4 weeks after diagnosis of type 1 diabetes, 10 subjects (pubertal males, 12-17 years old) will be randomized to either receive multiple daily injection (MDI) using Lantus insulin, or continuous subcutaneous insulin…
- Trial name
- NCT00357890
- Testing
- Insulin pump therapy, Multiple daily injections using insulin glargine + rapid acting analog
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Nemours Children's Clinic
Glycemic Control, Insulin
Insulin Degludec vs Insulin Glargine for Glycemic Control in Critical Illness Hyperglycemia
The role of ultralong insulin in the control of the blood glucose level in diabetic patients is well known, the current study will discuss the role of ultralong insulin in controlling of hyperglycaemia in critical illness defined…
- Conditions
- Glycemic Control, Insulin, Critical Illness
- Trial name
- NCT06178874
- Testing
- Insulin Glargine, Insulin Degludec, Insulin regular
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Ain Shams University
Diabetic Ketoacidosis
Effectiveness of Subcutaneous Glargine On The Time To Closure of The Anion Gap in Patients Presenting to the Emergency Department With Diabetic Keto-acidosis
To determine if co-administration of subcutaneous (SQ)Insulin glargine in combination with intravenous (IV) insulin decreases the time to resolution of ketoacidosis and requirement for ICU admission compared to IV insulin with…
- Trial name
- GT-COG (NCT02006342)
- Testing
- Insulin Glargine, Regular Insulin
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- The University of Texas Health Science Center, Houston
Type 1 Diabetes Mellitus
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus
Primary Objective: To compare the efficacy of a new formulation of insulin glargine and Lantus (overall, regardless the injection time) in terms of change of HbA1c from baseline to endpoint (scheduled Month 6) in participants…
- Trial name
- EDITION IV (NCT01683266)
- Testing
- HOE901-U300 (Insulin glargine new formulation), Lantus (Insulin glargine)
- Where
- 147 sites in United States, Canada and 11 more
- Volunteers
- 549 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 1
Comparing Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec and Insulin Glargine 300 U/mL at Steady-state Conditions in Subjects With Type 1 Diabetes Mellitus
This trial is conducted in Europe. The aim of this trial is to compare pharmacodynamic (the effect of the investigated drug on the body) and pharmacokinetic (the exposure of the trial drug in the body) properties of insulin…
- Trial name
- NCT02536859
- Testing
- insulin degludec, insulin glargine
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Comparing Pre-Mixed Insulin With Insulin Glargine Combined With Rapid-Acting Insulin in Patients With Type 2 Diabetes
The purpose of this study is to compare Lispro Mixture Therapy (insulin lispro 50/50 given three times daily with meals) to Glargine Basal-Bolus Therapy (insulin glargine daily with the addition of insulin lispro given three…
- Trial name
- NCT00110370
- Testing
- Lispro Mixture Therapy, Glargine Basal-Bolus Therapy
- Where
- 48 sites in United States, Puerto Rico
- Volunteers
- 300 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes
Lunch Time Insulin Injection by School Nurse for Poorly Controlled Diabetes
We hypothesize that checking blood sugar and taking long and short acting insulin before lunch at school may improve overall blood sugar control, grades, and decreases school absences in children and teens with poorly controlled…
- Trial name
- NCT00340613
- Testing
- glargine insulin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Baylor College of Medicine
Diabetes Mellitus, Type 1, Healthy Volunteers
A Study to Look at How Safe NNC0268-0965 is in Healthy People and People With Type 1 Diabetes
This study is investigating the safety and tolerability of the new medicine NNC0268-0965 (referred to as insulin 965), its concentrations in the blood and its effect on blood sugar for the treatment of diabetes.
- Trial name
- NCT03965013
- Testing
- NNC0268-0965, insulin glargine
- Where
- Germany
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 in T2DM
Efficacy and Safety of Basal Insulin Glargine Combination with Exenatide bid vs Switching Premix Human Insulin to Aspart30 in T2DM with Inadequate Glycaemic Control on Premixed Human Insulin and Metformin: a Randomized, Open…
- Trial name
- NCT02467920
- Testing
- glargine + exenatide, aspart 30
- Where
- China
- Volunteers
- 349 people
- Sponsor
- Huazhong University of Science and Technology
Prediabetes, Type 2 Diabetes
RISE Adult Medication Study
The RISE Adult Medication Study is a 4-arm, 3-center, clinical trial of adults with prediabetes and early type 2 diabetes to address the hypothesis that aggressive glucose lowering will lead to recovery of beta-cell function that…
- Trial name
- RISE Adult (NCT01779362)
- Testing
- Metformin, Liraglutide, Glargine
- Where
- 4 sites in United States
- Volunteers
- 267 people, healthy volunteers welcome
- Sponsor
- RISE Study Group
Diabetic Ketoacidosis
Use of Insulin Glargine to Treat Diabetic Ketoacidosis
The purpose of this study is to determine the effects of the addition of insulin glargine during the early phase of moderate to severe Diabetic Ketoacidosis (DKA) in children.
- Trial name
- NCT00179127
- Testing
- glargine, saline
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Vanderbilt University Medical Center
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
This trial is conducted in Asia, Europe and North America. The aim of the trial is to compare FIAsp (faster-acting insulin aspart) to insulin aspart, both in combination with insulin glargine and metformin in adults with type 2…
- Trial name
- onset® 2 (NCT01819129)
- Testing
- Faster-acting insulin aspart, Insulin aspart, Insulin glargine
- Where
- 144 sites in United States, Canada and 8 more
- Volunteers
- 881 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before
This study compares insulin 287 (a possible new medicine) to insulin glargine (a medicine doctors can already prescribe) in people with type 2 diabetes. Different ways of changing the dose of insulin 287 are also compared.
- Trial name
- NCT03951805
- Testing
- Insulin icodec, Insulin Glargine
- Where
- 43 sites in United States, Croatia and 5 more
- Volunteers
- 205 people
- Sponsor
- Novo Nordisk A/S
Type2diabetes
Effect of Short-term Basal Insulin Initiation in Newly Diagnosed Type 2 Diabetes on 1-year Glycemic Control
In this study, we aim to explore the beneficial effect of early short-term (two weeks), self-titrated, basal-only insulin therapy on the degree of glycemic control over 1-year follow through a prospective cohort.
- Trial name
- NCT06107153
- Testing
- Insulin Glargine 100 UNT/ML Pen Injector [Lantus], Saxagliptin 2.5 mg/ Metformin Hydrochloride extended release 1000 mg, Pioglitazone 30mg
- Where
- Iraq
- Volunteers
- 243 people
- Sponsor
- University of Basrah
Diabetes Mellitus, Type 2
Study to Optimize Insulin Treatment by Basal Regimen With Insulin Glargine in Type-2-Diabetic Patients Previously Uncontrolled on Premixed Insulin
Primary objective: To show an improvement in HbA1c control after 4 months of treatment with insulin glargine + Oral Anti Diabetic (OAD) in patients previously uncontrolled on premixed insulin (with OAD) Secondary objective…
- Trial name
- OPTIMIZATION (NCT00693771)
- Testing
- Insulin Glargine
- Where
- China
- Volunteers
- 313 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Better Acceptance of Single Injection Apidra Added to Once Daily Lantus Versus Twice Daily Premixed Insulin in Real Life Use Setting
Primary Objective: To demonstrate non-inferiority of once daily injection of insulin glargine (Lantus) plus one injection of mealtime insulin glulisine (Apidra) at the main meal versus twice daily premixed insulin (NovoMix 30/70)…
- Trial name
- BASAAL PLUS (NCT01079364)
- Testing
- Insulin glulisine, Insulin glargine, Premixed insulin (Insulin Aspart 30/70 )
- Where
- Netherlands
- Volunteers
- 52 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)
This 24-week study is a safety and efficacy comparison of MK-1293 and Lantus™ in participants with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT02059187
- Testing
- MK-1293, Lantus™, Prandial insulin
- Volunteers
- 531 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
The Korean TITRATION Study: Comparison of the Self-titration Methods for Glargine-300
The aim of this study is to demonstrate efficacy and safety of self-titration algorithm with Gla-300 using the INSIGHT algorithm (once daily by 1 unit) and the EDITION algorithm (once weekly by 3 units) in Korean patients with…
- Trial name
- NCT03406663
- Testing
- Group 1, Group 2
- Where
- South Korea
- Volunteers
- 130 people
- Sponsor
- Seoul National University Hospital
Type 1 Diabetes Mellitus
Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes
This is a single center, prospective, randomized, double blinded placebo controlled study conducted I patients with type 1 diabetes.The aim of this study is to examine the additive effects of GLP-1 agonist and SGLT2 inhibitor in…
- Trial name
- NCT02518945
- Testing
- Dapagliflozin, Insulin, Liraglutide
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University at Buffalo
Diabetes Mellitus, Type 2
A Clinical Trial Comparing Short-Term Efficacy and Safety of Exubera and Lantus
To compare short-term efficacy and safety of Exubera vs Lantus in patients with type 2 diabetes mellitus
- Trial name
- NCT00367445
- Testing
- Inhaled Human Insulin (Exubera), Insulin Glargine (Lantus)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Pfizer